BRPI0710883A2 - uso de um inibidor de gba2, e, composto - Google Patents
uso de um inibidor de gba2, e, composto Download PDFInfo
- Publication number
- BRPI0710883A2 BRPI0710883A2 BRPI0710883-4A BRPI0710883A BRPI0710883A2 BR PI0710883 A2 BRPI0710883 A2 BR PI0710883A2 BR PI0710883 A BRPI0710883 A BR PI0710883A BR PI0710883 A2 BRPI0710883 A2 BR PI0710883A2
- Authority
- BR
- Brazil
- Prior art keywords
- deoxinojirimycin
- group
- carbon atoms
- gba2
- use according
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims description 14
- 101100282794 Caenorhabditis elegans gba-2 gene Proteins 0.000 title description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 42
- 102100027814 Non-lysosomal glucosylceramidase Human genes 0.000 claims abstract description 35
- 101000859679 Homo sapiens Non-lysosomal glucosylceramidase Proteins 0.000 claims abstract description 27
- 239000012528 membrane Substances 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 12
- 108090000790 Enzymes Proteins 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 101710083785 Non-lysosomal glucosylceramidase Proteins 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 230000035772 mutation Effects 0.000 abstract description 4
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 230000003197 catalytic effect Effects 0.000 abstract description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical class OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 abstract 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 17
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 125000001841 imino group Chemical group [H]N=* 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 150000002772 monosaccharides Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 description 7
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 7
- 238000012937 correction Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- XVYLNHVEAOOEGI-FAIWKWDXSA-N (2r,3r,4r,5s)-1-[5-(1-adamantylmethoxy)pentyl]-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCOCC1(C2)CC(C3)CC2CC3C1 XVYLNHVEAOOEGI-FAIWKWDXSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000002132 lysosomal effect Effects 0.000 description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 4
- 102000011045 Chloride Channels Human genes 0.000 description 4
- 108010062745 Chloride Channels Proteins 0.000 description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002339 glycosphingolipids Chemical class 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940123455 Beta glucosidase inhibitor Drugs 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 150000002305 glucosylceramides Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZHMWOVGZCINIHW-FTYOSCRSSA-N 1-D-1,2-anhydro-myo-inositol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H]2O[C@H]21 ZHMWOVGZCINIHW-FTYOSCRSSA-N 0.000 description 1
- YUDPTGPSBJVHCN-YMILTQATSA-N 4-methylumbelliferyl beta-D-glucoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-YMILTQATSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-YIDFTEPTSA-N IDOSE Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-YIDFTEPTSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-UHFFFAOYSA-N N-palmitoyldihydro-sphingosine Natural products CCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710106714 Shutoff protein Proteins 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- LRUBQXAKGXQBHA-UHFFFAOYSA-N conduritol Chemical compound OC1C=CC(O)C(O)C1O LRUBQXAKGXQBHA-UHFFFAOYSA-N 0.000 description 1
- 229930191295 conduritol Natural products 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 101150073411 gba-2 gene Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79408806P | 2006-04-24 | 2006-04-24 | |
| US60/794088 | 2006-04-24 | ||
| PCT/NL2007/050177 WO2007123403A1 (en) | 2006-04-24 | 2007-04-24 | Improved treatment of cystic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0710883A2 true BRPI0710883A2 (pt) | 2011-08-09 |
Family
ID=38283020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0710883-4A BRPI0710883A2 (pt) | 2006-04-24 | 2007-04-24 | uso de um inibidor de gba2, e, composto |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8410081B2 (enExample) |
| EP (1) | EP2010551B1 (enExample) |
| JP (1) | JP2009538276A (enExample) |
| CN (1) | CN101479288B (enExample) |
| AT (1) | ATE479696T1 (enExample) |
| AU (1) | AU2007241622A1 (enExample) |
| BR (1) | BRPI0710883A2 (enExample) |
| CA (1) | CA2650311A1 (enExample) |
| DE (1) | DE602007008870D1 (enExample) |
| WO (1) | WO2007123403A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| ES2579628T3 (es) | 2009-02-23 | 2016-08-12 | Emergent Virology Llc | Iminoazúcares y métodos de tratamiento de enfermedades virales |
| EP2400843B1 (en) * | 2009-02-24 | 2015-11-11 | United Therapeutics Corporation | Iminosugars and methods of treating arenaviral infections |
| WO2010144759A1 (en) | 2009-06-12 | 2010-12-16 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
| JP5575246B2 (ja) * | 2009-09-04 | 2014-08-20 | ユナイテッド セラピューティクス コーポレイション | ポックスウイルス感染の治療方法 |
| EP2473482B1 (en) * | 2009-09-04 | 2014-03-05 | United Therapeutics Corporation | Methods of treating orthomyxoviral infections |
| CN102595895A (zh) * | 2009-09-04 | 2012-07-18 | 联合治疗公司 | 亚氨基糖以及治疗丝状病毒性疾病的方法 |
| GB201000499D0 (en) | 2010-01-13 | 2010-03-03 | Fleet George W J | Treatment of cystic fibrosis |
| WO2011095772A2 (en) | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| GB201006434D0 (en) | 2010-04-19 | 2010-06-02 | Summit Corp Plc | Novel iminosugar combinations |
| US10350277B2 (en) | 2011-09-07 | 2019-07-16 | Icahn School Of Medicine At Mount Sinai | Ceramidase and cell differentiation |
| ES2786128T3 (es) * | 2012-06-01 | 2020-10-08 | Icahn School Med Mount Sinai | Niveles de ceramida en el tratamiento y prevención de infecciones |
| WO2014086934A1 (en) * | 2012-12-05 | 2014-06-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Diagnosis of cystic fibrosis |
| JP6832158B2 (ja) | 2013-03-14 | 2021-02-24 | アイカーン スクール オブ メディシン アット マウント サイナイ | 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法 |
| US20190142782A1 (en) | 2016-04-11 | 2019-05-16 | Spedding Research Solutions | Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units |
| HRP20251697T1 (hr) | 2017-06-01 | 2026-02-27 | Idorsia Pharmaceuticals Ltd | Kristalni oblik n-butildeoksigalaktonojirimicina |
| MX2023010658A (es) * | 2021-03-12 | 2023-10-30 | Excepgen Inc | Sistemas y metodos para la expresion de proteinas. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177447B1 (en) * | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| AU5799500A (en) | 1999-06-29 | 2001-01-22 | Mcgill University | Human alpha 1,2-mannosidase |
| EP1528056A1 (en) * | 2003-10-29 | 2005-05-04 | Academisch Ziekenhuis bij de Universiteit van Amsterdam | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors |
| FR2861991B1 (fr) * | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| WO2005123055A2 (en) | 2004-06-14 | 2005-12-29 | Musc Foundation For Research Development | Methods for treating inflammatory disorders |
| CN101267779A (zh) * | 2005-07-27 | 2008-09-17 | 福罗里达大学研究基金会有限公司 | 使用热休克治疗眼睛疾病 |
-
2007
- 2007-04-24 DE DE602007008870T patent/DE602007008870D1/de active Active
- 2007-04-24 BR BRPI0710883-4A patent/BRPI0710883A2/pt not_active IP Right Cessation
- 2007-04-24 CA CA002650311A patent/CA2650311A1/en not_active Abandoned
- 2007-04-24 US US12/298,506 patent/US8410081B2/en not_active Expired - Fee Related
- 2007-04-24 EP EP07747401A patent/EP2010551B1/en not_active Not-in-force
- 2007-04-24 CN CN2007800237886A patent/CN101479288B/zh not_active Expired - Fee Related
- 2007-04-24 WO PCT/NL2007/050177 patent/WO2007123403A1/en not_active Ceased
- 2007-04-24 AU AU2007241622A patent/AU2007241622A1/en not_active Abandoned
- 2007-04-24 AT AT07747401T patent/ATE479696T1/de not_active IP Right Cessation
- 2007-04-24 JP JP2009507606A patent/JP2009538276A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007241622A8 (en) | 2008-12-04 |
| CN101479288B (zh) | 2012-06-27 |
| DE602007008870D1 (de) | 2010-10-14 |
| EP2010551B1 (en) | 2010-09-01 |
| ATE479696T1 (de) | 2010-09-15 |
| CA2650311A1 (en) | 2007-11-01 |
| EP2010551A1 (en) | 2009-01-07 |
| US20090186862A1 (en) | 2009-07-23 |
| WO2007123403A1 (en) | 2007-11-01 |
| CN101479288A (zh) | 2009-07-08 |
| AU2007241622A1 (en) | 2007-11-01 |
| US8410081B2 (en) | 2013-04-02 |
| JP2009538276A (ja) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2010551B1 (en) | Improved treatment of cystic fibrosis | |
| Colell et al. | Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor‐κB‐dependent survival pathway | |
| US20020115619A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
| ES2354976T3 (es) | Fosfatasa alcalina placentaria para controlar la diabetes. | |
| US8148354B2 (en) | Use of 20(S)-protopanaxadiol in manufacture of antidepressants | |
| BR112019016316A2 (pt) | Métodos para o tratamento da influenza | |
| Finnie et al. | Stimulation of colonic mucin synthesis by corticosteroids and nicotine | |
| Fischer et al. | A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells | |
| PT1663185E (pt) | Prevenção e tratamento de perda óssea induzida por inflamação e/ou imunomediada | |
| US20100286256A1 (en) | Compositions and methods for therapy for diseases characterized by defective chloride transport | |
| Roomans | Pharmacological approaches to correcting the ion transport defect in cystic fibrosis | |
| EA016082B1 (ru) | Применение r-сальбутамола для местного лечения накожных форм красной волчанки | |
| PT1680112E (pt) | N-(5-adamantano-1-il-metoxi-pentil)desoxinojirimicina ou um seu sal aceite na indústria farmacêutica para ser usado no tratamento da resistência à insulina | |
| BRPI0708273A2 (pt) | uso de compostos de hexoses | |
| BRPI0718522A2 (pt) | Uso de um composto, e, método de tratamento para reduzir os níveis de triglicerídeo, colesterol e/ou glicose no sangue | |
| WO2017037041A1 (en) | Use of indole compounds to stimulate the immune system | |
| US5929035A (en) | Methods of treating intestinal disorders | |
| Reid et al. | Control and modulation of airway epithelial cells and their secretions | |
| Gillissen et al. | Beta-2-Agonists Have Antioxidant Function in vitro. 2. The Effect of Beta-2-Agonists on Oxidant-Mediated Cytotoxicity and on Superoxide Anion Generated by Human Polymorphonuclear Leukocytes: 2. The Effect of Beta-2-Agonists on Oxidant-Mediated Cytotoxicity and on Superoxide Anion Generated by Human Polymorphonuclear Leukocytes | |
| Mygind | Progress in the drug management of allergic rhinitis | |
| KR20060025607A (ko) | 염증성 장 질환의 예방 및(또는) 치료제 | |
| Naclerio | Additional properties of cetirizine, a new H1 antagonist | |
| KR20100126326A (ko) | 알츠하이머 병 치료용 의약의 제조를 위한 ｓ-아데노실메티오닌(ｓａｍ) 및 슈퍼옥시드 디스뮤타아제(ｓｏｄ)의 용도 | |
| Rajakulasingam et al. | The influence of terfenadine and ipratropium bromide alone and in combination on bradykinin‐induced nasal symptoms and plasma protein leakage | |
| US20250205249A1 (en) | Composition for use in enhancing, boosting, restoring and/or preventing the decline of cognitive functions, adjuvant composition, method for using the composition or adjuvant composition, and kit having the composition or adjuvant composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES. |